Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sadra Medical, a medical device firm, has announced the enrollment and treatment of four new patients in the second phase of its European feasibility study of the Sadra Lotus Valve system.
Subscribe to our email newsletter
The Lotus Valve system is designed to enable physicians to replace a diseased aortic valve utilizing a less invasive approach, navigating the valve through the patient’s arteries using a catheter-based delivery system and thereby eliminating the need for an open chest surgical procedure.
According to the company, the Sadra Lotus Valve system, designed to be retrievable and repositionable, helps improve and streamline the procedure that, ultimately, may enable treatment for a broader group of patients.
The company has also announced that co-founder and board member, Fred Khosravi, has accepted the role of chairman of the board.
Eberhard Grube, principal investigator for the Sadra Lotus Valve European feasibility study, said: “The percutaneous aortic valve replacement (PAVR) procedure using the Sadra Lotus Valve is enhanced by the ease of placement and the ability to safely reposition or retrieve the valve. Based upon the one year follow-up from the first patient and my experience involved in treating this latest set of patients, I am very encouraged about the Lotus Valve’s potential to improve the PAVR procedure.”